

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
Zanubrutinib	BTK inhibitor	CLL/SLL				US, EU (CLL), Canada, China, UK, Mexico, UAE, Switzerland, Thailand, South Africa, and others
		WM				US, EU, Canada, LATAM, and others
		R/R FL				US, Canada, Thailand, China, Switzerland, UK
		R/R MZL				US, EU, Canada, UK, AU, Singapore, S Korea, Thailand, LATAM, UAE, Kuwait
		R/R MCL				US, Canada, Israel, LATAM, and others
		R/R DLBCL				
		Previously treated B-cell malignancies				
Sonrotoclax	BCL2 inhibitor	TN CLL*				
		R/R WM				
		R/R CLL				
		R/R MCL				
		R/R MM with t(11;14) [†]				
		Myeloid malignancies [‡]				
		B-cell malignancies				
BGB-16673	BTK-targeted CDAC	B-cell malignancies				
BGB-21447	BCL2 inhibitor	B-cell malignancies				
BGB-10188	PI3Kδ inhibitor	B-cell malignancies				
AMG 176 [§]	MCL-1 inhibitor	Hematologic malignancies				
Tislelizumab	anti-PD-1	R/R cHL				China
Ociperlimab	anti-TIGIT	R/R DLBCL				

Safety and efficacy have not been established for investigational products and/or uses.

BCL2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MCL-1, myeloid cell leukemia-1; MM, multiple myeloma; MZL, marginal zone lymphoma; PD-1, programmed cell death protein 1; PI3Kδ, phosphoinositide 3-kinase delta; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; WM, Waldenström macroglobulinemia.

LATAM: Argentina, Brazil, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Honduras, Mexico, Nicaragua, Panama, and Uruguay.

* in combination with Zanubrutinib.

[†]+Dexamethasone +/- Carfilzomib.

[‡]+Azacitidine +/- Posaconazole.

[§] Amgen collaboration, BeiGene has China commercial rights.